5 Key Takeaways

• 1

  Alcon received FDA approval for Tryptyr, a first-in-class TRPM8 receptor agonist, for treating dry eye disease (DED).

• 2

  Tryptyr demonstrated rapid natural tear production, showing significant results as early as Day 1 in phase 3 clinical trials.

• 3

  In trials, 42.6% of Tryptyr patients had a 10 mm increase in tear production by Day 14, compared to 8.2% in the vehicle group.

• 4

  Tryptyr is administered as one drop per eye, twice daily, and will be available in the U.S. in the third quarter of 2025.

• 5

  This approval marks Alcon's first prescription pharmaceutical treatment since becoming an independent eyecare company.